If You Can Relate To Any Of The Issues Below,
This Advanced Nootropic Memory Patch May Be Perfect For You
- Are you experiencing any short or long-term memory issues? Are you studying for a big exam? Are you preparing an important business presentation?
- Have you ever walked into a room for something and forgotten what you walked in for? Are you having trouble concentrating or focusing?
- Did you ever start to read a “new” book, only to realize that you already read it? Have you ever “blanked-out” on the names of people you know real well?
Nootropic Transdermal Time-Release Memory Patch
According to the Merriam Webster Medical Dictionary "nootropics" are drugs, supplements, nutraceuticals, and functional foods that promote the enhancement of cognition and memory and the facilitation of learning. As such, “nootropics” are much more than just plain stimulants.
- Nootropics will give you the dopamine spike that's required to be productive without impairing your focus.
- Nootropics will give your brain the extra boost that's required for maximal cognitive performance, but they won't overclock your synapses or set you up to an inevitable crash when their potent effects begin to wear off.
- Nootropics will have a lasting beneficial effect on your ability to remember facts, figures, names and all sort of information without being addictive or putting you at risk of forgetting all the valuable information, when you stop taking them.
In short, nootropics will have you performing at the top of your mental game!!!!
Unfortunately, in isolation none of the currently available over-the-counter agents will deliver cognitive enhancement, increases in processing speed and capacity, and improved memory function at the same time. To compensate for the functional shortcomings of each of the currently available agents, our research team has developed a science-backed formula that delivers a precisely formulated blend of five synergistically acting agents:
- Noopept was developed at the Zakusov Research Institute of Pharmacology at the Russian Academy of Medical Sciences as a fundamentally new, safe nootropic agent for the use in health and disease in the late 1980s (Ostrovskaia. 2001).
- Structurally, Noopept is similar to the better-known nootropic piracetam. Its effects on cognition, however, are significantly more pronounced than those of its cousin (see Figure 1).
Due to the fact that Noopept has a relatively low oral bioavailability of (lower than 10% according to Boiko. 2004), the AgeForce® time-released transdermal delivery technology makes Noopept an even more effective nootropic agent (Boiko. 2004).
Next to its nootropic prowess, Noopept has also been shown to have potent anti-oxidant and anti-inflammatory effects (Kovalenko. 2001; Alekseeva. 2011) – effects, of which recent studies show that they act right at the level of the synapses, where they will protect your brain from oxidative damage, as well as peripherally. In fact, a very recent rodent study suggests that the anti-inflammatory effects of Noopept are potent enough to alleviate the increases in blood glucose and body weight and normalize the pain sensitivity in diabetic rodents (Ostrovskaya. 2013).
In addition, Noopept has been shown to directly stimulate the release of the neurotropic growth factors NGF and BDNF in the brain. Thus, Noopept will promote increases in neuronal plasticity and trigger neuronal repair (Ostrovskaya. 2008a, 2008c & 2010). An effect that will result in long-term increases in cognitive function in healthy individuals and curative effects in individuals with brain disorders – including hitherto untreatable diseases like Alzheimer's, where initial rodent studies suggest that Noopept can be used to restore normal brain function in the early stages of the disease (Ostrovskaya. 2007 & 2008b; Jia. 2011). Similar beneficial effects have observed in various models of stroke (Romanova. 2003 & 2005) and severe brain ischemia (Us. 2005).
Huperzine A is a very potent cholinesterase inhibitor (Liu. 1986) which means that that Huperzine A will effectively increase both the level and duration of action of the neurotransmitter acetylcholine. When it's administered in the correct dosages, Huperzine A will thus loosen the natural brake on your brains neurotransmitter system and allow your neuronal network to operate at maximal performance.
Just like Noopept, Huperzine A has been suggested as a cognitive enhancer and neuroprotective agent that is potent enough to be of interest for the treatment of Alzheimer's disease (Xu. 1999; Camps. 2000; Zangara. 2003).
Huperzine A is a natural constituent from Huperzia serrata, which has been used as a nootropic agent in traditional Chinese medicine for centuries. In the late 1990, Huperzine A has undergone several double blind, placebo-controlled clinical trials with subjects suffering from various memory disorders (1990) who experienced improvements in overall life quality in all and significant improvements in memory in 60% of cases.
As Zangara et al. point out, "both animal and human safety evaluations have demonstrated that HupA is devoid of unexpected toxicity" (Zangara. 2003).
Yet despite its high potency (recommended dosages are in the microgram range) and moderate oral bioavailability its rapid clearance would require repeated administration over the course of the day (Qian. 1995) – an issue that is eliminated with the time-released transdermal delivery technology of the Nootropic Memory Enhancer Patch.
Vinpocetine is a semisynthetic derivative of the vinca alkaloid vincamine that has been isolated from the plant in 1975 by the Hungarian chemist Csaba Szántay. It is a powerful vasodilator and nootropic agent that will improve cognitive performance by enhancing cerebral metabolism (Kiss. 1996).
Just like Noopept, Vinpocetine has been shown to exert potent anti-inflammatory effects in a whole host of animal and human studies. Accordingly, scientists believe that it may have a potential role in the treatment of Parkinson's and Alzheimer's disease (Jeon. 2010; Medina. 2010). Its beneficial effects, which include – among other things – a significant increase in glucose uptake that will contribute to its overall beneficial effects on cerebral energy metabolism (Shibota. 1982) make Vinpocetine interesting for both, healthy and cognitively impaired individuals who are looking for ways to boost their brain performance naturally.
In their review relatively recent 2012 of the literature, Jha, Rahman and Sheikh list the following benefits in their list of science backed "extraordinary characteristics" (Jha. 2012) of Vinpocetine, which will:
- Improve long and short term memory,
- Enhance alertness,
- Serve as a neuroprotector,
- Improve the delivery and utilization of glucose and oxygen to your brain,
- Improve blood flow in your brain,
- Act to enhance dopaminergic, serotonergic, noradrenergic functions,
- Prevent ischemic damage in the brain, muscle tissue, liver and elsewhere,
- Prevent epileptic seizures,
- Diminish senile cerebral dysfunction,
- Prevent excitotoxic (excessive receptor excitement) cell death in the brain,
- Reduce cerebral anoxic (absence of oxygen) damage,
- And much more
And that's just an excerpt from the long list the researchers from the Pokhara University in Nepal and the neighboring Bangladesh University compiled. Also on that list are: Improvement in visual and hearing function, mood enhancement, and muscle relaxant and heart protective effects.
In the end, the aforementioned health effects are yet just a nice bonus to the core effects of Vinpocetine: Significant increases in memory performance!
In this respect, it is particularly striking that that the already significant increase in memory retrieval increases, when the amount of information that has to be remembered increases (see Figure 3).
One thing Vinpocetine has in common with all the other agents in the Nootropic Memory Enhancer Patch is its limited biovailability of max. 7% (Vereczkey. 1978; Grandt. 1989; Szakács. 2011). And while both, ingesting Vinpocetine with a meal and (Lohmann. 1992) and using Nano sized Vinpocetine peparations and increase its originally low bioavailability, even the high tech oral formulations fall short of the average bioavailability that can be achieved with the advanced transdermal delivery system of the Nootropic Memory Enhancer Patch (Luo. 2006).
Unlike several other currently available nootropics that have not found their way onto the ingredient list of the Nootropic Memory Enhancer Patch, Vinpocetin has been shown to be side effect free. In a clinically controlled long-term study in elderly patients by Frenzel et al. (1986) the subjects used comparatively high amounts of Vinoceptine for a whole without experiencing significant side effects.
Yohimbine is a well-known mildly stimulant traditional aphrodisiac and constituent of many over-the-counter fat burners. The fact that the alpha-2 adrenoreceptor antagonist will also improve human information processing, however, is more or less unknown.
As a study from the University of California, San Francisco, indicates, Yohimbine will significantly improve the reaction times during a set of standardized cognitive performance tests in young, healthy volunteers (Halliday. 1989).
In conjunction with its mild MAOI effects and the resulting increase in the activity of naturally produced dopamine and serotonin, Yohimbine is thus the perfect complement to the "classic" nootropic agents in the Nootropic Memory Enhancer Patch.
A complement, by the way, even those of you who have experienced anxiety or other side effects with oral Yohimbine formulations can benefits from. Due to the slow delivery of the active ingredients from the Nootropic Memory Enhancer Patch, the already rare side effects some of the users of oral Yohimbine supplements experience are not an issue you would have to be concerned about.
Hordenine is the last ingredient in the synergistically formulated Nootropic Memory Enhancer blend. Hordenine is a naturally occurring alkaloid in barley, cactus and several other plants. Hordenine has been shown to inhibit the reuptake of noradrenaline (Barwell. 1989) and will thus augment the natural increase of catecholamines and the corresponding increase in alertness (Smith. 2003)
Alekseeva, S. V., et al. "[An experimental study of the anti-inflammatory action of Noopept and its effect on the level of cytokines]." Eksperimental'naia i klinicheskaia farmakologiia 75.9 (2011): 25-27.
Barwell, C. J., et al. "Deamination of hordenine by monoamine oxidase and its action on vasa deferentia of the rat." Journal of pharmacy and pharmacology 41.6 (1989): 421-423. Boiko, S. S., et al. "Bioaccessibility of the new dipeptide nootropic drug Noopept." Pharmaceutical Chemistry Journal 38.12 (2004): 645-647.
Camps, Pelayo, et al. "New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease." Journal of medicinal chemistry 43.24 (2000): 4657-4666.
Fenzl, E., et al. "Long-term study concerning tolerance and efficacy of vinpocetine in elderly patients suffering from a mild to moderate organic psychosyndrome." Senile Dementias: Early Detection. Szerk.: Bes A. et al.: John Libbey Eurotext (1986): 580-585.
Grandt, R., et al. "Vinpocetine pharmacokinetics in elderly subjects." Arzneimittel-Forschung 39.12 (1989): 1599-1602.
Gudasheva, T. A., et al. "Peptide analogs of piracetam as ligands of presumptive nootrope receptors."Khim.-Farm. Zh. 11 (1985): 1322–1329.
Halliday, R., E. Callaway, and R. Lannon. "The effects of clonidine and Yohimbine on human information processing." Psychopharmacology 99.4 (1989): 563-566.
Jeon, Kye-Im, et al. "Vinpocetine inhibits NF-κB–dependent inflammation via an IKK-dependent but PDE-independent mechanism." Proceedings of the National Academy of Sciences 107.21 (2010): 9795-9800.
Jha, M. K., M. H. Rahman, and Hasib Sheikh. "Vinpocetine: a smart drug and a smart nutrient: a review." IJPSR 3.2 (2012): 346-352.
Jia, Xueen, et al. "Neuroprotective and nootropic drug Noopept rescues α-synuclein amyloid cytotoxicity." Journal of molecular biology 414.5 (2011): 699-712.
Kiss, B., and E. Karpati. "[Mechanism of action of Vinpocetine]." Acta Pharmaceutica Hungarica 66.5 (1996): 213-224.
Kovalenko, L. P., et al. "[Anti-inflammatory properties of Noopept (dipeptide nootropic agent GVS-111)]." Eksperimental'naia i klinicheskaia farmakologiia 65.2 (2001): 53-55.
Lohmann, A., et al. "Bioavailability of vinpocetine and interference of the time of application with food intake." Arzneimittel-Forschung 42.7 (1992): 914-917.
Luo, YiFan, et al. "Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability." Journal of controlled release 114.1 (2006): 53-59.
Medina, Alexandre E. "Vinpocetine as a potent antiinflammatory agent." Proceedings of the National Academy of Sciences 107.22 (2010): 9921-9922.
Medina, Alexandre E. "Vinpocetine as a potent antiinflammatory agent." Proceedings of the National Academy of Sciences 107.22 (2010): 9921-9922.
Neznamov, G. G., and E. S. Teleshova. "Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin." Neuroscience and behavioral physiology 39.3 (2009): 311-321.
Ostrovskaia, R. U., et al. "[On the mechanism of Noopept action: decrease in activity of stress-induced kinases and increase in expression of neutrophines]." Eksperimental'naia i klinicheskaia farmakologiia 73.12 (2010): 2-5.
Ostrovskaia, R. U., et al. "[The original novel nootropic and neuroprotective agent Noopept]." Eksperimental'naia i klinicheskaia farmakologiia 65.5 (2001): 66-72.
Ostrovskaya, R. U., A. P. Belnik, and Z. I. Storozheva. "Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by β-amyloid25–35 injection into Meynert basal nuclei of rats)." Bulletin of experimental biology and medicine 146.1 (2008b): 77-80.
Ostrovskaya, R. U., A. P. Belnik, and Z. I. Storozheva. "Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by β-amyloid₂₅₋ ₃₅ injection into Meynert basal nuclei of rats)." Bulletin of experimental biology and medicine. Bi︠︡ulletenʹ ėksperimentalʹnoĭ biologii i medit︠︡siny (2008c).
Ostrovskaya, R. U., et al. "Efficiency of Noopept in Streptozotocin-Induced Diabetes in Rats." Bulletin of experimental biology and medicine 154.3 (2013): 334-338.
Ostrovskaya, R. U., et al. "Noopept stimulates the expression of NGF and BDNF in rat hippocampus." Bulletin of experimental biology and medicine 146.3 (2008a): 334-337.
Ostrovskaya, Rita U., et al. "The nootropic and neuroprotective proline-containing dipeptide Noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model." Journal of Psychopharmacology 21.6 (2007): 611-619.
Qian, Bo-Chu, et al. "Pharmacokinetics of tablet huperzine A in six volunteers." Zhongguo yao li xue bao= Acta pharmacologica Sinica 16.5 (1995): 396-398.
Romanova, G. A., et al. "Effects of Noopept in the photochemically induced stroke model." Biopolymers. Vol. 71. No. 3. 111 RIVER ST, HOBOKEN, NJ 07030 USA: JOHN WILEY & SONS INC, 2003.
Romanova, G. A., et al. "P. 5.072 Memory restoring and neuroprotective effects of dipeptide Noopept in a photochemical stroke model." European Neuropsychopharmacology 15 (2005): S241.
Smith, Andrew, et al. "Caffeine and central noradrenaline: effects on mood, cognitive performance, eye movements and cardiovascular function." Journal of Psychopharmacology 17.3 (2003): 283-292.
Szakács, Tünde, Zsuzsa Veres, and László Vereczkey. "In vitro-in vivo correlation of the pharmacokinetics of vinpocetine." Polish journal of pharmacology 53.6 (2001): 623-628.
Us, K. S., S. A. Gavrilova, and V. B. Koshelev. "P. 5.066 Neuroprotective properties of the novelnootropic dipeptide Noopept (GVS-111) on the model of severe brain ischemia." European Neuropsychopharmacology 15 (2005): S238.
Vereczkey, L., et al. "Pharmacokinetics of vinpocetine in humans." Arzneimittel-Forschung 29.6 (1978): 957-960.
Xu, S. S., et al. "Huperzine-A in capsules and tablets for treating patients with Alzheimer disease." Zhongguo yao li xue bao= Acta pharmacologica Sinica 20.6 (1999): 486-490.
Zangara, Andrea. "The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease." Pharmacology Biochemistry and Behavior 75.3 (2003): 675-686.